Stablepoint Partners LLC Has $1.38 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Stablepoint Partners LLC cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 4.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,993 shares of the company’s stock after selling 939 shares during the quarter. Stablepoint Partners LLC’s holdings in AstraZeneca were worth $1,375,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Martin Investment Management LLC lifted its stake in shares of AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after acquiring an additional 7,615 shares during the last quarter. Nordea Investment Management AB bought a new position in AstraZeneca in the fourth quarter valued at about $754,000. Diversify Wealth Management LLC boosted its stake in shares of AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after purchasing an additional 153 shares in the last quarter. Ameritas Advisory Services LLC grew its holdings in shares of AstraZeneca by 25.9% during the fourth quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock worth $622,000 after purchasing an additional 1,949 shares during the last quarter. Finally, Integrated Advisors Network LLC increased its stake in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $69.06 on Monday. The company has a market capitalization of $214.16 billion, a PE ratio of 33.04, a P/E/G ratio of 1.13 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The firm has a fifty day simple moving average of $66.44 and a 200 day simple moving average of $74.17.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the company posted $0.87 EPS. The business’s quarterly revenue was up 18.0% on a year-over-year basis. On average, sell-side analysts forecast that AstraZeneca PLC will post 4.12 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.